30 Regardless of rupture location, repair is indicated for patients of all ages irrespective of the activity level
Kim KW, Williams JW, Wang YT et al (2016) MHC II+ resident peritoneal and pleural macrophages rely on IRF4 for development from circulating monocytes
Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively
launched July 1, 2026 through December 31, 2027 Who Faces the Greatest Need for This Coverage The groups most likely to benefit from the Medicare GLP-1 Bridge program include: Medicare Part D enrollees ages 65 and older with a body mass index of 35 or higher, or a BMI of 27 or higher combined with a qualifying condition such as cardiovascular disease or prediabetes Adults with obesity who were previously unable to afford brand-name GLP-1 medications on fixed retirement incomes People who discontinued brand-name GLP-1 treatment due to cost and are eligible to re-enter with the $50 Bridge copay Patients managing obesity-related conditions including hypertension, sleep apnea, and prediabetes, who may reduce downstream healthcare costs through weight management People who already receive GLP-1 coverage through their Part D plan for diabetes, cardiovascular disease, or sleep apnea do not qualify for the Bridge program they continue to access the drugs through their existing coverage
2025 (Frontiers in Nutrition) Cross-sectional dietary study of 69 GLP-1 users
